Another 32 proprietary Chinese medicines in Shanxi have been withdrawn from the Internet!

On November 23, Shanxi Province Pharmaceutical Equipment Centralized Bidding Purchasing Network issued the "Notice on Announcement of Some Enterprises' Application for Revocation of Online Procurement Eligibility for Platforms" (hereinafter referred to as the "Notice"), and 32 Chinese patent medicines including Qingreling Granules will be removed from the Internet , Involving 8 pharmaceutical companies
.
According to the "Notice", according to relevant regulations, 32 drug product regulations of 8 drug manufacturers including Guizhou Shuangsheng Pharmaceutical Co.
, Ltd.
have applied for the cancellation of platform-linked procurement qualifications.
The above-mentioned companies will not accept the product to be listed again within two years after the cancellation of the network.
Net
.
The publicity time is from November 23 to November 26, 2021
.
The 32 Chinese patent medicines withdrawn this time are many familiar and commonly used varieties, including Qiwei Turmeric Liniment, Vitamin C Yinqiao Tablets, Xiangguo Jianxiao Tablets, Shengmai Capsules, Qingreling Granules, Ningxinbao Capsules, Astragalus Injection , Motherwort particles, SGR nourishing oral liquid
.
The 8 pharmaceutical manufacturers involved, including Guizhou Shuangsheng Pharmaceutical, Guizhou Bailing, Yunnan Yunhe Pharmaceutical, Zhengda Qingchunbao Pharmaceutical, Hubei Minkang Pharmaceutical, Liaoning Shangyao Good Nurse Pharmaceutical, Tiansheng Pharmaceutical, Guangxi Baiqi Pharmaceutical Industry
.
Among them, Minkang Pharmaceutical has 17 drug product regulations withdrawn from Shanxi, including Buzhong Yiqi Pills, Guipi Pills (Concentrated Pills), Liuwei Dihuang Pills (Concentrated Pills), Zhibai Dihuang Pills (Concentrated Pills), Tianwang Tonic Heart pill (concentrated pill) and other varieties
.
In recent years, under the influence of stricter industry supervision, the Chinese patent medicine market has ushered in great changes.
In addition, the inclusion of Chinese patent medicines in centralized procurement has become a “fix”
.
On August 9 this year, the National Medical Insurance Bureau responded to the "Recommendations on Accelerating the Entry of Traditional Chinese Medicines and Formula Granules into Centralized Procurement" and stated that it would start with high-priced and large-volume varieties and speed up the inclusion of proprietary Chinese medicines and formula granules into centralized procurement
.
This also means that Chinese medicine companies will face pressure to cut prices in the future
.
In this context, some traditional Chinese medicine companies with small sales have chosen to directly give up their qualifications for listing their products and devote their energy to other channels
.
Frequent actions of Chinese medicine companies withdrawing from the Internet in Shanxi Province
.
Just last month, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Procurement Center issued the "Notice on Publicizing Some Enterprises' Application for Revocation of Platform-based Procurement Eligibility", including Telmisartan Tablets, Huanglian Shangqing Pills, Vinorelbine Tartrate Injection, and Hydrochloric Acid 118 drug product regulatory applications including ranitidine capsules, fluconazole sodium chloride injection, ribavirin injection, etc.
have been withdrawn from the network, involving companies such as Dongyang Sunshine, Bosen Bio, Suzhong Pharmaceutical, Wanglaoji, etc.

.
Among them, Beijing Tongrentang, a large traditional Chinese medicine company, withdrew from Shanxi 31 drug product regulations including Wuji Baifeng Pills and other large varieties, accounting for about 30% of the total number of withdrawals
.
How will such a big move affect the company? Prior to this, Tongrentang stated in its annual report that the bidding and purchasing methods of medicines in various regions had little effect on the company's product sales, because the share of online recruitment and procurement sales was relatively small
.
At present, Tongrentang medicines are mainly sold through traditional distributor channels.
In addition, Tongrentang's own retail pharmacies are also an important sales channel
.
From the perspective of the industry, traditional Chinese medicine companies such as Beijing Tongrentang make the decision to withdraw from the Internet.
Generally, they have their own brand advantages and can directly face the market to sell their own drugs.
However, it should be noted that retail channels are often compared to public hospitals.
It consumes more energy for the enterprise, and if the market is not well controlled, various disadvantages will inevitably occur
.